Live Attenuated Vaccines for RSV and COVID-19
Meissa is developing live attenuated vaccines against life threatening respiratory viruses, including respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19), and human metapneumovirus (hMPV). Meissa’s vaccine candidates are formulated to be delivered as a single, intranasal, adjuvant-free, needle-free dose, that is economical to produce and can be scaled rapidly to supply global demands. These vaccine candidates have been developed using the company’s proprietary AttenuVax platform and are designed to prevent infection and disease and safely generate a strong, durable immune response.
AttenuVax : Optimized Immunity
RSV and SARS-CoV-2 are both life-threatening respiratory viruses that suppress the immune system resulting in a poor immune response. Meissa’s AttenuVax platform generates vaccine candidates that are highly attenuated and specifically optimized to induce a better immune response than natural infection.